Answers are grounded in this paper and cite their sources.
The decline in cell-associated HIV DNA observed throughout one year treatment indicated that HAART reduces the proviral HIV-DNA load more effectively when initiated during the primary rather than the chronic phase of HIV infection. These findings therefore tend to lend support to the early initiation of treatment. Nevertheless, heterogeneous baseline values observed for CD4 cell count, plasma HIV RNA and proviral HIV DNA in PRIMO subjects, raise the question of whether treatment should be delayed in some to spare early adverse effects of HAART.
No takes yet. Share an insight, caveat, or question.
Ngo‐Giang‐Huong et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: